The reimbursement environment for diagnostics company LipoScience (NASDAQ:LPDX) is not going to change in a quarter's time and with that, neither will the commercial/financial situation change all that much. LipoScience remains what it has been for some time - a company with a very interesting cholesterol test, one that measures the actual number of cholesterol particles and not just the overall amount of cholesterol in the blood, but a company that definitely needs to sell payers and clinicians on the importance of this test and its role in health care management.
If LipoScience can accumulate and present the data necessary to sway insurance companies and doctors, $100 million in annual revenue in five years' time and $200 million...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|